- Home
- SSL vs ARQT Comparison
SSL vs ARQT Comparison
Compare SSL & ARQT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SSL | ARQT |
|---|---|---|
| Founded | 1950 | 2016 |
| Country | South Africa | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.8B | 3.3B |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | SSL | ARQT |
|---|---|---|
| Price | $6.17 | $29.03 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $24.83 |
| AVG Volume (30 Days) | 823.7K | ★ 2.4M |
| Earning Date | 01-01-0001 | 10-28-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.59 | N/A |
| Revenue | ★ $14,028,282,389.00 | $317,929,000.00 |
| Revenue This Year | $1.17 | $85.51 |
| Revenue Next Year | $6.50 | $30.74 |
| P/E Ratio | $10.55 | ★ N/A |
| Revenue Growth | N/A | ★ 129.21 |
| 52 Week Low | $2.78 | $11.13 |
| 52 Week High | $7.39 | $31.77 |
Technical Indicators
Market Signals| Indicator | SSL | ARQT |
|---|---|---|
| Relative Strength Index (RSI) | 43.95 | 56.09 |
| Support Level | $5.97 | $28.30 |
| Resistance Level | $6.43 | $31.77 |
| Average True Range (ATR) | 0.12 | 1.08 |
| MACD | -0.04 | -0.43 |
| Stochastic Oscillator | 33.60 | 22.77 |
Price Performance
Historical ComparisonAbout SSL Sasol Ltd.
Sasol Ltd operates as a vertically integrated chemicals and energy company through its two main businesses: the Southern Africa Energy & Chemicals business and the International Chemical business. It generates maximum revenue from the Southern Africa Energy & Chemicals business, which operates integrated value chains with feedstock sourced from the Mining and Gas operating segments. Geographically, the company generates the majority of its revenue from South Africa.
About ARQT Arcutis Biotherapeutics Inc.
Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.